User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study

Primary tabs

download
  • Open access
  • PDF
  • 148.29 K
Mysler, Eduardo F. Spindler, Alberto J. Guzman, Renato Bijl, Marc Jayne, David Houssiau, Frédéric [UCL] Brunetta, Paul

Objective To investigate the efficacy and safety of ocrelizumab in patients with class III/IV lupus nephritis (LN). Methods Patients were randomized 1:1:1 to receive placebo, 400 mg ocrelizumab, or 1,000 mg ocrelizumab given as an intravenous infusion on days 1 and 15, followed by a single infusion at week 16 and every 16 weeks thereafter, accompanied by background glucocorticoids plus either mycophenolate mofetil (MMF) or the Euro-Lupus Nephritis Trial (ELNT) regimen (cyclophosphamide followed by azathioprine). The study was terminated early due to an imbalance in serious infections in ocrelizumab-treated patients versus placebo-treated patients. We report week 48 efficacy data for patients receiving ≥32 weeks of treatment (n = 223) and safety results for all treated patients (n = 378). Results The overall renal response rate was 54.7%, 66.7%, 67.1%, and 66.9% in the placebo-treated, 400 mg ocrelizumab-treated, 1,000 mg ocrelizumab-treated, and combined ocrelizumab-treated groups, respectively. The associated treatment difference versus placebo for the combined ocrelizumab-treated groups was 12.7% (95% confidence interval [95% CI] -0.8, 26.1) (P = 0.065), with similar differences observed for both ocrelizumab-treated groups. Ocrelizumab versus placebo treatment differences were apparent in patients receiving the background ELNT regimen, but not in those receiving background MMF. A numerically greater proportion of ocrelizumab-treated patients had a ≥50% reduction in the urinary protein:urinary creatinine ratio at 48 weeks compared with placebo-treated patients (placebo-treated patients, 58.7%; 400 mg ocrelizumab-treated patients, 70.7%; 1,000 mg ocrelizumab-treated patients, 68.5%). Serious adverse events occurred in 27.2% of placebo-treated patients, 35.7% of 400 mg ocrelizumab-treated patients, and 22.0% of 1,000 mg ocrelizumab-treated patients. Corresponding serious infection rates (events/100 patient-years) were 18.7 (95% CI 12.2, 28.7), 28.8 (95% CI 20.6, 40.3), and 25.1 (95% CI 17.4, 36.1), respectively. The imbalance in serious infections with ocrelizumab occurred with background MMF but not with the background ELNT regimen. Conclusion In patients with active LN, overall renal response rates with ocrelizumab were numerically but not statistically significantly superior to those with placebo. Ocrelizumab treatment was associated with a higher rate of serious infections in the subgroup receiving background MMF. Copyright © 2013 by the American College of Rheumatology.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2013
Language Anglais
Journal information "Arthritis & Rheumatism" - Vol. 65, no. 9, p. 2368-2379 (2013)
Peer reviewed yes
Publisher John Wiley & Sons, Inc. ((United States) Hoboken, NY)
issn 0004-3591
e-issn 1529-0131
Publication status Publié
Affiliations UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales
UCL - (SLuc) Service de rhumatologie
Links
  1. Saxena Ramesh, Mahajan Tina, Mohan Chandra, Lupus nephritis: current update, 10.1186/ar3378
  2. Weening J. J., The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited, 10.1097/01.asn.0000108969.21691.5d
  3. Houssiau FA, Ginzler EM, Current treatment of lupus nephritis, 10.1177/0961203308090029
  4. D’Cruz DP, Houssiau FA, The Euro-Lupus Nephritis Trial: the development of the sequential treatment protocol, 10.1177/0961203309106892
  5. Houssiau Frédéric A., Vasconcelos Carlos, D'Cruz David, Sebastiani Gian Domenico, Garrido Enrique de Ramon, Danieli Maria Giovanna, Abramovicz Daniel, Blockmans Daniel, Mathieu Alessandro, Direskeneli Haner, Galeazzi Mauro, Gül Ahmet, Levy Yair, Petera Peter, Popovic Rajko, Petrovic Radmila, Sinico Renato Alberto, Cattaneo Roberto, Font Josep, Depresseux Geneviève, Cosyns Jean-Pierre, Cervera Ricard, Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide : Immunosuppressive Therapy in Lupus Nephritis, 10.1002/art.10461
  6. Walsh M., James M., Jayne D., Tonelli M., Manns B. J., Hemmelgarn B. R., Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis, 10.2215/cjn.01200307
  7. Houssiau Frédéric A., Toward Better Treatment for Lupus Nephritis, 10.1056/nejme1111089
  8. Dooley Mary Anne, Jayne David, Ginzler Ellen M., Isenberg David, Olsen Nancy J., Wofsy David, Eitner Frank, Appel Gerald B., Contreras Gabriel, Lisk Laura, Solomons Neil, Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis, 10.1056/nejmoa1014460
  9. Appel G. B., Contreras G., Dooley M. A., Ginzler E. M., Isenberg D., Jayne D., Li L.-S., Mysler E., Sanchez-Guerrero J., Solomons N., Wofsy D., , Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis, 10.1681/asn.2008101028
  10. Ginzler Ellen M., Dooley Mary Anne, Aranow Cynthia, Kim Mimi Y., Buyon Jill, Merrill Joan T., Petri Michelle, Gilkeson Gary S., Wallace Daniel J., Weisman Michael H., Appel Gerald B., Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis, 10.1056/nejmoa043731
  11. Hahn Bevra H., McMahon Maureen A., Wilkinson Alan, Wallace W. Dean, Daikh David I., FitzGerald John D., Karpouzas George A., Merrill Joan T., Wallace Daniel J., Yazdany Jinoos, Ramsey-Goldman Rosalind, Singh Karandeep, Khalighi Mazdak, Choi Soo-In, Gogia Maneesh, Kafaja Suzanne, Kamgar Mohammad, Lau Christine, Martin William J., Parikh Sefali, Peng Justin, Rastogi Anjay, Chen Weiling, Grossman Jennifer M., American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis, 10.1002/acr.21664
  12. Bertsias George K, Tektonidou Maria, Amoura Zahir, Aringer Martin, Bajema Ingeborg, Berden Jo H M, Boletis John, Cervera Ricard, Dörner Thomas, Doria Andrea, Ferrario Franco, Floege Jürgen, Houssiau Frederic A, Ioannidis John P A, Isenberg David A, Kallenberg Cees G M, Lightstone Liz, Marks Stephen D, Martini Alberto, Moroni Gabriela, Neumann Irmgard, Praga Manuel, Schneider Matthias, Starra Argyre, Tesar Vladimir, Vasconcelos Carlos, van Vollenhoven Ronald F, Zakharova Helena, Haubitz Marion, Gordon Caroline, Jayne David, Boumpas Dimitrios T, Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis, 10.1136/annrheumdis-2012-201940
  13. Pradhan VandanaD, Patwardhan ManishaM, Ghosh Kanjaksha, Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies, 10.4103/0378-6323.60558
  14. Pisetsky David S., Anti-DNA and autoantibodies : , 10.1097/00002281-200009000-00002
  15. Manson Jessica J, Ma Alexander, Rogers Pauline, Mason Lesley J, Berden Jo H, Vlag Johan, D'Cruz David P, Isenberg David A, Rahman Anisur, Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study, 10.1186/ar2831
  16. Chang A., Henderson S. G., Brandt D., Liu N., Guttikonda R., Hsieh C., Kaverina N., Utset T. O., Meehan S. M., Quigg R. J., Meffre E., Clark M. R., In Situ B Cell-Mediated Immune Responses and Tubulointerstitial Inflammation in Human Lupus Nephritis, 10.4049/jimmunol.1001983
  17. Arbuckle Melissa R., McClain Micah T., Rubertone Mark V., Scofield R. Hal, Dennis Gregory J., James Judith A., Harley John B., Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus, 10.1056/nejmoa021933
  18. Navarra Sandra V, Guzmán Renato M, Gallacher Alberto E, Hall Stephen, Levy Roger A, Jimenez Renato E, Li Edmund K-M, Thomas Mathew, Kim Ho-Youn, León Manuel G, Tanasescu Coman, Nasonov Eugeny, Lan Joung-Liang, Pineda Lilia, Zhong Z John, Freimuth William, Petri Michelle A, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, 10.1016/s0140-6736(10)61354-2
  19. Melander C., Sallee M., Trolliet P., Candon S., Belenfant X., Daugas E., Remy P., Zarrouk V., Pillebout E., Jacquot C., Boffa J.-J., Karras A., Masse V., Lesavre P., Elie C., Brocheriou I., Knebelmann B., Noel L.-H., Fakhouri F., Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome, 10.2215/cjn.04030808
  20. Lu Tim Y.-T., Ng Kristine P., Cambridge Geraldine, Leandro Maria J., Edwards Jonathan C. W., Ehrenstein Michael, Isenberg David A., A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patients, 10.1002/art.24341
  21. Díaz-Lagares Cándido, Croca Sara, Sangle Shirish, Vital Edward M., Catapano Fausta, Martínez-Berriotxoa Agustín, García-Hernández Francisco, Callejas-Rubio José-Luis, Rascón Javier, D'Cruz David, Jayne David, Ruiz-Irastorza Guillermo, Emery Paul, Isenberg David, Ramos-Casals Manuel, Khamashta Munther A., Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts, 10.1016/j.autrev.2011.10.009
  22. Rovin Brad H., Furie Richard, Latinis Kevin, Looney R. John, Fervenza Fernando C., Sanchez-Guerrero Jorge, Maciuca Romeo, Zhang David, Garg Jay P., Brunetta Paul, Appel Gerald, , Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study, 10.1002/art.34359
  23. Genovese Mark C., Kaine Jeffrey L., Lowenstein Mitchell B., Giudice José Del, Baldassare Andrew, Schechtman Joy, Fudman Edward, Kohen Michael, Gujrathi Sheila, Trapp Robert G., Sweiss Nadera J., Spaniolo Greg, Dummer Wolfgang, , Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study, 10.1002/art.23732
  24. Tak P. P., Mease P. J., Genovese M. C., Kremer J., Haraoui B., Tanaka Y., Bingham C. O., Ashrafzadeh A., Travers H., Safa-Leathers S., Kumar S., Dummer W., Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial, 10.1002/art.33353
  25. Rigby W., Tony H.-P., Oelke K., Combe B., Laster A., von Muhlen C. A., Fisheleva E., Martin C., Travers H., Dummer W., Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial, 10.1002/art.33317
  26. Tan Eng M., Cohen Alan S., Fries James F., Masi Alfonse T., Mcshane Dennis J., Rothfield Naomi F., Schaller Jane Green, Talal Norman, Winchester Robert J., The 1982 revised criteria for the classification of systemic lupus erythematosus : REVISED CRITERIA FOR SLE, 10.1002/art.1780251101
  27. Ginzler Ellen M, Wax Stephen, Rajeswaran Anand, Copt Samuel, Hillson Jan, Ramos Eleanor, Singer Nora G, Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial, 10.1186/ar3738
  28. Mak A., Cheak A. A. C., Tan J. Y. S., Su H. C., Ho R. C. M., Lau C. S., Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression, 10.1093/rheumatology/kep120
  29. Kappos Ludwig, Li David, Calabresi Peter A, O'Connor Paul, Bar-Or Amit, Barkhof Frederik, Yin Ming, Leppert David, Glanzman Robert, Tinbergen Jeroen, Hauser Stephen L, Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial, 10.1016/s0140-6736(11)61649-8
Bibliographic reference Mysler, Eduardo F. ; Spindler, Alberto J. ; Guzman, Renato ; Bijl, Marc ; Jayne, David ; et. al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. In: Arthritis & Rheumatism, Vol. 65, no. 9, p. 2368-2379 (2013)
Permanent URL http://hdl.handle.net/2078.1/164079